![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Wockhardt Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Pramipexole dihydrochloride monohydrate, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2012-149 - Rev 00
This Chemical Type CEP, issued on July 15, 2014, remains in force until April 29, 2019, ensuring its reliability within the pharmaceutical industry.
Substance Number 2416 associated with this CEP further emphasizes